A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma

AIM: A Phase II trial of bevacizumab plus tandutinib. METHODS: We enrolled 41 recurrent, bevacizumab-naive glioblastoma patients for a trial of bevacizumab plus tandutinib. Median age was 55 and 71% were male. Treatment consisted of tandutinib 500 mg two-times a day (b.i.d.) and bevacizumab 10 mg/kg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:CNS Oncol
Autors principals: Odia, Yazmin, Sul, Joohee, Shih, Joanna H, Kreisl, Teri N, Butman, John A, Iwamoto, Fabio M, Fine, Howard A
Format: Artigo
Idioma:Inglês
Publicat: Future Medicine Ltd 2016
Matèries:
Clinical Trial Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5514626/
https://ncbi.nlm.nih.gov/pubmed/26860632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2015-0010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars